Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies

Yu Mori (yu-mori@med.tohoku.ac.jp)
Tohoku University Graduate School of medicine https://orcid.org/0000-0002-8225-4690

Takuya Izumiyama
Tohoku University: Tohoku Daigaku

Hiroaki Kurishima
Tohoku University: Tohoku Daigaku

Masayuki Kamimura
Tohoku University: Tohoku Daigaku

Kazuyoshi Baba
Tohoku University: Tohoku Daigaku

Naoko Mori
Tohoku University: Tohoku Daigaku

Eiji Itoi
Tohoku University: Tohoku Daigaku

Research article

Keywords: Denosumab, Rheumatoid arthritis, Anti-cyclic citrullinated peptide antibody, Bone erosion, Joint destruction, Modified total Sharp score

DOI: https://doi.org/10.21203/rs.3.rs-129845/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Introduction: This study aimed to determine the effects of denosumab treatment on the joint destruction of Japanese females with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (CCP) antibodies.

Materials and Methods: This retrospective longitudinal study included 56 patients treated with denosumab and 50 patients treated with bisphosphonate. All participants were positive for anti-CCP antibodies. All patients also had a history of osteoporosis treatment with bisphosphonate, which was either continued or switched to 60 mg of subcutaneous denosumab injection every 6 months. To assess the progression of joint destruction, hand and foot radiographs were taken, and changes in modified total Sharp score (mTSS), erosion score (ERO) and joint space narrowing score (JSN) were evaluated at 12 months and 24 months. The changes in BMD of the lumbar spine and hip were also assessed at 12 months.

Results: At 12 months, there were significant differences in the change of ERO (p = 0.015) and mTSS (p = 0.01). Similarly, there were significant differences in the change of ERO (p = 0.013) and mTSS (p = 0.003) at 24 months. In contrast, no significant difference was observed in the changes of JSN and clinical parameters. There were significant differences in the changes in BMD in the femoral neck (p = 0.011) and total hip (p = 0.012).

Conclusion: Denosumab treatment might be effective for the inhibition of bone erosion progression in the patients with RA, and it potentially contributes to the treatment of osteoporosis and prevention of destructive arthritis in patients with switching treatment from bisphosphonate.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammatory synovitis and bone and cartilage destruction [1,2]. Patients with RA also carry a risk of general bone loss and osteoporosis [3-5]. Destructive arthritis and general bone loss are considered to be related to activated osteoclasts. The receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) and its related signals are essential for osteoclast development, activation and survival [1,2,6-8]. Proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1, IL-6 and IL-17 are related with the induction of RANKL in inflammatory cells, such as T lymphocytes and synovial cells [9,10]. Bone resorption and destruction by activated RANKL signaling are associated with the progression of joint deformation with active synovitis. In contrast, the progression of bone erosion and destruction are observed in patients without marked synovial inflammation [11]. Thus, RANKL pathway seems to be activated in patients with RA regardless of inactivated synovitis.

Denosumab is a fully human monoclonal IgG2 antibody, which acts by binding RANKL and suppressing the activity of the RANKL signaling pathway. The suppression of RANKL by denosumab inhibits the bone resorption of osteoclasts and may prevent bone erosion and joint deformity in an experimental arthritis model [12]. Randomized control studies and systematic reviews demonstrated the therapeutic effects of
denosumab for the prevention of osteoporosis and osteoporotic fractures in postmenopausal patients [13-16]. In contrast, a few randomized control studies and several small-scale clinical studies were performed for the assessment of the therapeutic effects of the denosumab for the prevention of bone erosion in the patients with RA [11,17-20]. The results of these studies demonstrated the inhibition of bone erosion progression compared with placebo. These studies were conducted among patients with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), including methotrexate. On the other hand, the patients with RA with biological DMARDs (bDMARDs) were not included in these studies, and the effect of denosumab in the prevention of the bone erosion in the patients with RA treated with bDMARDs still remains unclear. A previous study reported that denosumab had significantly reduced bone erosion in patients with anti-cyclic citrullinated peptide (anti-CCP), which is a risk factor for radiographic damage [21]. However, no other studies have demonstrated the relation between anti-CCP antibody and the prevention effect of denosumab against bone erosion. The therapeutic effects of denosumab for bone erosion among patients with a positive anti-CCP antibody status has not been determined. In addition, previous studies reported the effect of denosumab in the prevention of bone erosion for only 12 months; no studies have reported the long-term effects of denosumab yet. The continuity of the denosumab for inhibition of bone destruction was also undetermined.

The main aim of the present study was to evaluate the effect of denosumab treatment on joint destruction inhibition in patients with anti-CCP antibodies. In the clinical setting, refractory patients with RA have been treated with bDMARDs for synovial inflammation and inhibition of joint destruction. This study included patients with RA treated with bDMARDs and tested the inhibition of bone erosion in participants with bDMARDs treatment to clarify the efficacy of denosumab for the prevention of bone erosion, even in the presence of bDMARD treatment. We also evaluated the effect of denosumab on the improvement of BMD and prevention of osteoporotic fractures.

Materials And Methods

Patients

This retrospective longitudinal study was conducted in accordance with the ethical standards of the Declaration of Helsinki and approved by the Institutional Review Board of our institute (Approval number: 2020-1-814). Informed consent was obtained from all patients before participation in this study. The study population included 106 Japanese postmenopausal female patients with RA and osteoporosis, according to the American College of Rheumatology (ACR) classification criteria (1987) or ACR/European League against Rheumatism criteria [22,23]. All patients were positive for anti-CCP antibodies, and also fulfilled the Japanese society of Osteoporosis criteria for the diagnosis of glucocorticoid-induced osteoporosis or primary osteoporosis [24,25]. Patients were enrolled at our institution from April 2015 through March 2020. All patients had a history of bisphosphonate treatment; they either continued bisphosphonate treatment or switched to subcutaneous injection of 60 mg of denosumab every 6 months. The reasons for switching from bisphosphonates to denosumab were patient preference for convenience and inadequate improvement in bone mineral density by bisphosphonates. In addition, all
patients were treated with an active form of Vitamin D. 0.75 mg of eldecalcitol or 1mg of alphacalcidol were administered before the enrollment of the study. We excluded patients with parathyroid disease, chronic severe renal dysfunction, hypocalcemia, and malabsorption disease, as well as patients who had been treated with parathyroid hormone and romosozumab. Furthermore, we excluded patients with avascular necrosis of the hip and vertebral fractures caused by high-velocity injuries.

**Clinical variables**

Baseline general characteristics were recorded in detail, including age, height, bodyweight and body mass index (BMI) in patients with RA at the start of the study. We measured the RA disease activity by calculating composite disease activity scores (DAS). C-reactive protein based DAS28 (DAS28-CRP) includes the number of swollen and tender joints (out of a total of 28), a global visual analog scale (VAS) score, and the C-reactive protein level. The titer of anti-CCP antibody and matrix metalloproteinase-3 (MMP3) were also assessed. The Health Assessment Questionnaire (HAQ) was administered to assess functional disability. All clinical assessments were performed at baseline and at 12 months of follow-up. The duration of disease and treatment of rheumatoid arthritis were also recorded.

**Radiographic assessment of the modified Sharp Score**

Hand and foot radiographs were taken at baseline, 12 months and 24 months. For the assessment of the modified total sharp score (mTSS), two rheumatologists independently assessed the radiographs using the modified Sharp/van der Heijde method with blinded clinical information of patients, and the average score was calculated and used in the analysis [11,26]. Changes in the modified Sharp erosion score (ERO), modified Sharp joint space narrowing score (JSN) and mTSS were evaluated at 12 and 24 months. The structural remission rate at 12M (the change of mTSS $\leq 0.5$) was calculated in bisphosphonates and denosumab treatment groups [23].

**Bone mineral density measurement and vertebral fracture assessment**

Bone mineral density (BMD) measurement and vertebral fracture assessment were performed as previously described in the literature [27]. We measured BMD (g/cm$^2$) at the AP lumbar spine (vertebrae L2–4) and left hip (total hip and femoral neck) by using dual-energy X-ray absorptiometry (Discovery DXA system; Hologic, Waltham, MA, USA). All procedures were performed according to the manufacturer’s standardized protocols at baseline and 12 months. All BMD results were expressed as absolute values (g/ cm$^2$). Thoracolumbar radiographs were obtained in all patients to detect vertebral fractures, including both painful vertebral fractures and asymptomatic morphologic vertebral fractures at baseline and 12 months.

**Statistical analysis**

All results were expressed as the mean ± standard deviation. At baseline, 12 months and 24 months, comparisons of clinical parameters between denosumab and bisphosphonate treatment groups were performed using the Mann–Whitney U test. This test was also performed to identify the differences in the
change in BMD of the lumbar spine, femoral neck, and total hip between two groups at 12 months. Similarly, the changes of mTSS, ERO and JSN were compared using Mann–Whitney U test between the groups at 12 months and 24 months. The structural remission rate at 12M (the change of mTSS \leq 0.5) was compared using Mann–Whitney U test. The usage of bDMARDs, bisphosphonates and active form of vitamin D were compared between two groups using Fisher’s exact tests. All statistical tests were two-sided, with a p value of less than 0.05 considered statistically significant. All analyses were performed using JMP version 15 (SAS, Cary, NC, USA).

**Results**

In this study, sixteen patients with RA using bisphosphonate and 12 patients with RA using denosumab were not included in the study because they were negative for anti-CCP antibodies. Finally, 106 postmenopausal Japanese women with rheumatoid arthritis were enrolled. There were 50 and 56 patients in the bisphosphonate-continuing group and the denosumab group, respectively. There were no apparent side effects of bisphosphonates and denosumab during the treatment, including hypocalcemia and interstitial pneumonia. Table 1 shows the clinical characteristics of these two groups. Significant intergroup differences were observed related to age [67.6 (7.4) vs. 71.1 (8.2), p = 0.035] and usage of methotrexate [38 (76%) vs. 26 (46.4), p = 0.02]. There were no significant differences in body weight, BMI, and usage of prednisone and bDMARDs, including etanercept, golimumab, tocilizumab, sarilumab and abatacept. In the assessment of disease activity of RA, such as DA28-CRP and the titer of anti-CCP antibody, and joint deformity including ERO, JSN and mTSS, there were no significant differences between the two groups. Similarly, there were no significant differences between the groups in the comparison of BMD and previous vertebral fractures. The usage of bisphosphonates and active form of vitamin D were shown in appendix table 1. There were no significant differences in the usage of bisphosphonates and vitamin D between two groups.

The scores of mTSS, JSN and ERO at baseline, 12 months and 24 months are shown in Figure 1, respectively. There were no significant differences between the two groups. Figure 2 shows clinical scores of DAS28-CRP, VAS and mHAQ at baseline, 12 months and 24 months, respectively. There were no significant differences between the groups.

Table 2 compares of the changes of ERO, JSN, mTSS scores, and clinical scores at 12 months. There were significant differences in the change of ERO [1.16 (1.47) vs. 0.72 (1.58), p = 0.015] and mTSS [1.56 (2.15) vs. 1.12 (2.31), p = 0.01]. Cumulative probability blots for the changes in ERO, JSN and mTSS scores at 12 months are shown in Figure 3. A higher structural remission rate (the change of mTSS \leq 0.5) was observed in the denosumab treatment group (28 vs. 58.9%; p<0.001). In contrast, no significant difference was observed in the change of JSN and clinical parameters, including DAS28-CRP, VAS and mHAQ.

Table 3 demonstrates the comparison of the changes of ERO, JSN and mTSS at 24 months. There were significant differences in the change of ERO [1.56 (1.62) vs. 1.07 (2.38), p = 0.013] and mTSS [2.52 (2.97)
vs. 1.73 (4.36), \( p = 0.003 \). Cumulative probability blots for the changes in ERO, JSN and mTSS scores at 24 months are shown in Figure 4. Similar to the assessment at 12 months, no significant differences were observed in the change of JSN and clinical parameters, including DAS28-CRP, VAS and mHAQ.

The BMD of lumbar spine, femoral neck and total hip at baseline and 12 months are shown in Figure 5. There were no significant differences between the two groups.

The changes of BMD were shown in Table 4. There were significant differences related to the BMD changes of femoral neck \([0.0045 (0.033) \text{ vs. } 0.021 (0.042), p = 0.011]\) and total hip \([0.0042 (0.056) \text{ vs. } 0.027 (0.062), p = 0.012]\). In contrast, there were no significant differences in the BMD of lumbar spine and the incidence of vertebral fractures.

**Discussion**

The present study observed significant differences related to the change of mTSS and ERO between bisphosphonate treatment group and denosumab treatment group in patients with a positive anti-CCP antibody status at 12 and 24 months. In contrast, there was no significant difference in the change of JSN. Similarly, significant differences were observed in the change of BMD of femoral neck and total hip between the groups. However, there was no significant difference in the change of BMD of lumbar spine. These results are consistent with previously conducted large-scale studies \([11,18,21]\). In this study, patients undergoing bDMARDs treatment were enrolled in both groups. Denosumab treatment was effective for the inhibition of bone erosion, even in the presence of bDMARDs. The present study included the patients with switching treatment from bisphosphonate to denosumab and demonstrated the efficacy of the switching treatment for the inhibition of the bone erosion and destruction, like as the improvement of BMD in patients with RA.

Previous studies have also discussed the efficacy of denosumab for the inhibition of bone erosion. The changes in mTSS were remarkably greater in patients with anti-CCP antibodies \([21]\). The anti-CCP antibody titer has been demonstrated as a predictor of bone erosion and destruction in patients with RA \([28,29]\). Patients with anti-CCP antibodies were likely to have the risk of advanced radiographic progression. However, denosumab demonstrated significant inhibition of bone erosion in patients with anti-CCP antibodies \([21]\). These results were consisted with those of present study. These findings indicted that denosumab is expected to suppress the progression of bone erosion and destruction in patients with anti-CCP antibody positive status.

Previous studies were performed to identify the effect of denosumab treatment on the inhibition of bone erosion and destruction in The patients with RA without treatment history of bisphosphonate and bDMARDs \([11,18,21]\). Osteoporosis treatment guidelines recommend bisphosphonate at first-line treatment for patient with risks of osteoporosis and osteoporotic fractures \([24,25]\). Patients with rheumatological disease have the high risks of general bone loss and osteoporotic fractures, and should be treated with bisphosphonate or denosumab \([30,31]\). Therefore, patients with RA without a history of bisphosphonate and bDMARD treatment seemed to be uncommon and different from actual clinical
settings. In contrast, some studies indicated that the effect of switching treatment from bisphosphonates to denosumab for the improvement of BMD in patients with RA. However, previous studies did not demonstrate the effect of the prevention of bone erosion and destruction by switching bisphosphonates to denosumab [32,33]. Since the present study included patients treated with bDMARDs and bisphosphonates, it can be assumed that the study was conducted under conditions similar to actual clinical practice. The present study was the first to demonstrate the efficacy of the switching treatment from bisphosphonate to denosumab for the inhibition of bone erosion and destruction.

The mTSS was the sum of ERO and JSN. The significant difference in mTSS and ERO between the two groups was considered to reflect the inhibitory effect of denosumab on bone erosion. On the other hand, there was no significant difference in JSN, suggesting that neither denosumab nor bisphosphonate had an inhibitory effect on cartilage destruction. In this study, the increase in mTSS at 12 months in the bisphosphonate and denosumab groups exceeded 0.5, which did not correspond to structural remission [23]. However, a higher structural remission rate (the change of mTSS \( \leq \) 0.5) was observed in the denosumab treatment group (28 vs. 58.9%; \( p<0.001 \)). The results suggest that switching denosumab treatment from bisphosphonate may be advantageous for structural remission.

In this study, we compared and observed the inhibitory effect of denosumab on bone erosion and destruction at 12 and 24 months after switching treatment. Previous studies have confirmed the inhibitory effect of denosumab on bone erosion at 12 months [11,18,21], but its effects over a longer period of time remain undetermined. To our best knowledge, the present study was the first to demonstrate the inhibitory effect of denosumab on inhibition of bone erosion and destruction over a 24-month period.

The results of the present study demonstrated that the changes in BMD of femoral neck and total hip were significantly higher in denosumab group. In contrast, there was no significant difference in the change of BMD of lumbar spine. The participants in this study fulfilled the criteria of either bisphosphonate continuation group or the denosumab switchover group; no bisphosphonate-naive patients were included. Therefore, we considered the possibility that significant differences in BMD of lumbar spine was not observed between the two groups due to the effect of the prior bisphosphonate use. Furthermore, a previous study reported that degenerative disease of the lumbar spine and previous vertebral fracture increased the BMD of the lumbar spine in elderly patients [34]. Other studies have reported that the BMD of the femur had a stronger association with the risk factors of osteoporosis compared to the BMD of the lumbar spine in patients with rheumatological diseases [5,35]. The authors considered that lack of a significant difference in the change of lumbar spine BMD may have been due to its susceptibility to age-related degeneration and vertebral fractures.

There are several limitations in the present study. First, the present study was performed as a retrospective study and the number of patients was small. Authors did not perform the adjustment of confounding factors of participants in this study. Further large-scale prospective studies with the adjustment of confounding factors are required to confirm the results in this study. Second, the treatment
agents of rheumatoid arthritis and treatment duration were not uniform among the study patients. Therefore, future studies should consider assessing the treatment effect of denosumab for erosion inhibition in patients with uniform RA treatment history. Third, the types of bisphosphonates used prior to the enrollment of this study and the duration of their use were not uniform. The types of bisphosphonates used continuously were also not uniform. Fourth, the measurement of anti-CCP antibody was not performed after denosumab treatment. The effect of denosumab for decreasing the titer of anti-CCP antibody remained unclear. Finally, the serum bone turnover markers and serum vitamin D levels were not measured in the present study.

In conclusion, the present study indicated significant differences related to the change of mTSS and ERO between bisphosphonate and denosumab treatment groups in the patients with a positive anti-CCP antibody status. In contrast, denosumab treatment did not affect the change of JSN. Similarly, denosumab treatment provided greater improvement in the BMD of the femoral neck and total hip. Denosumab treatment was effective for the inhibition of bone erosion, even in the presence of bDMARDs. Denosumab may contribute to both the treatment of osteoporosis and the prevention of the destructive arthritis in patients with RA. The results of present study are exploratory, and the authors consider that further follow-up is needed for causal inference.

**Abbreviations**

**ACPA:** Anti-cyclic citrullinated peptide antibody  
**ACR:** American College of Rheumatology  
**BMD:** Bone mineral density  
**BMI:** Body mass index  
**CCP:** Cyclic citrullinated peptide  
**CRP:** C reactive protein  
**DAS:** Disease activity score  
**DMARDs:** Disease-modifying antirheumatic drugs  
**ERO:** modified Sharp erosion  
**HAQ:** Health Assessment Questionnaire  
**IL:** Interleukin  
**JSN:** modified Sharp joint space narrowing  
**MMP3:** Matrix metalloproteinase-3
mTSS: modified total Sharp score

MTX: methotrexate

RA: Rheumatoid arthritis

RANK: Receptor activator of nuclear factor kappa B

RANKL: Receptor activator of nuclear factor kappa B ligand

TNF-α: tumor necrosis factor-alpha

VAS: Visual analogue scale

Declarations

Disclosures

None.

Declarations

Funding

None.

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was approved by the Institutional Review Board of Tohoku University Hospital.

Consent to participate

Informed consent was obtained from all patients in accordance with the Declaration of Helsinki before participating in this study.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.
**Code availability**

Not applicable.

**Authors’ contributions**

YM, TI, and NM mainly collected the clinical data. YM, TI, NM and EI interpreted the data through discussion. All the authors participated in manuscript writing and editing. All authors approved the final version of the manuscript.

**References**

1. McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389:2328-37 doi:10.1016/S0140-6736(17)31472-1

2. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023-38 doi:10.1016/S0140-6736(16)30173-8

3. Heinlen L, Humphrey MB (2017) Skeletal complications of rheumatoid arthritis. Osteoporos Int 28:2801-12 doi:10.1007/s00198-017-4170-5

4. Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23-7 doi:10.1016/s0140-6736(94)91049-9

5. Mori Y, Kuwahara Y, Chiba S, Kogre A, Baba K, Kamimura M, Itoi E (2017) Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment. J Bone Miner Metab 35:52-57 doi:10.1007/s00774-015-0716-9

6. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinoshita K, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597-602 doi:10.1073/pnas.95.7.3597

7. Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, Fujimura S, Koga T, Nakamura A, Takayanagi H, Itoi E, Takai T (2008) Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol 181:4742-51 doi:10.4049/jimmunol.181.7.4742

8. Kamimura M, Mori Y, Sugahara-Tobinai A, Takai T, Itoi E (2015) Impaired Fracture Healing Caused by Deficiency of the Immunoreceptor Adaptor Protein DAP12. PLoS One 10:e0128210 doi:10.1371/journal.pone.0128210

9. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259-69 doi:10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W

10. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS (2005) Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1:47-54 doi:10.1038/ncprheum0036
11. Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D (2019) Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis 78:899-907 doi:10.1136/annrheumdis-2018-214827

12. Kostenuik PJ, Nguyen HQ, McCabe J, Warminston KS, Kurahara C et al. (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182-95 doi:10.1359/jbmr.081112

13. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-65 doi:10.1056/NEJMoa0809493

14. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-57 doi:10.1210/jc.2007-2814

15. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R et al. (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513-23 doi:10.1016/S2213-8587(17)30138-9

16. Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27:2835-44 doi:10.1007/s00198-016-3607-6

17. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R, Denosumab Rheumatoid Arthritis Study G (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299-309 doi:10.1002/art.23417

18. Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75:983-90 doi:10.1136/annrheumdis-2015-208052

19. Ebina K, Hirao M, Hashimoto J, Matsuoka H, Iwahashi T, Chijimatsu R, Etani Y, Okamura G, Miyama A, Yoshikawa H (2018) Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naive rheumatoid arthritis. Osteoporos Int 29:1627-36 doi:10.1007/s00198-018-4492-y
20. Mochizuki T, Yano K, Ikari K, Kawakami K, Hiroshima R, Koenuma N, Ishibashi M, Momohara S (2018) Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis. J Bone Miner Metab 36:431-38 doi:10.1007/s00774-017-0848-1

21. Tanaka Y, Soen S, Ishiguro N, Yamanaka H, Yoneda T, Tanaka S, Ohira T, Nitta T, Okubo N, Genant H, van der Heijde D, Takeuchi T (2020) Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open 6 doi:10.1136/rmdopen-2020-001249

22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-24 doi:10.1002/art.1780310302

23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT et al. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580-8 doi:10.1136/ard.2010.138461

24. Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337-50 doi:10.1007/s00774-014-0586-6

25. Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for B, Mineral R, Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary O (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247-57 doi:10.1007/s00774-013-0447-8

26. van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27:261-3

27. Mori Y, Izumiya T, Baba K, Mori N, Fujii H, Ishii T, Itoi E (2020) Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis. J Orthop Surg Res 15:290 doi:10.1186/s13018-020-01813-4

28. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewe R, Kvien TK (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67:212-7 doi:10.1136/ard.2006.068247

29. Forslind K, Ahlmen M, Eberhard K, Hafstrom I, Svensson B, Group BS (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090-5 doi:10.1136/ard.2003.014233

30. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-9 doi:10.1056/NEJM199807303390502
31. Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF (2019) Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis Rheumatol 71:1174-84 doi:10.1002/art.40874

32. Kaneko T, Okamura K, Yonemoto Y, Okura C, Suto T, Tachibana M, Sakane H, Inoue M, Chikuda H (2019) Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates. J EXP ORTOP 6: 41 doi.org/10.1186/s40634-019-0211-7

33. Nakamura Y, Suzuki T, Kato H (2017) Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis. Arch Osteoporos 12: 80 doi.org/10.1007/s11657-017-0371-y

34. Muraki S, Yamamoto S, Ishibashi H, Horiuchi T, Hosoi T, Orimo H, Nakamura K (2004) Impact of degenerative spinal diseases on bone mineral density of the lumbar spine in elderly women. Osteoporos Int 15:724-8 doi:10.1007/s00198-004-1600-y

35. Mori Y, Baba K, Kogure A, Izumiyama T, Matsuda M, Mori N, Ishii T, Itoi E (2018) Assessment of the risk of low bone mineral density in premenopausal Japanese female patients with systemic lupus erythematosus. J Orthop 15:89-93 doi:10.1016/j.jor.2018.01.029

Tables

Table 1 Comparison of clinical measurements in the patients with RA treated with bisphosphonates and denosumab at enrollment
| Variable                  | Bisphosphonate group (n=50) | Denosumab group (n=56) | p value |
|---------------------------|-----------------------------|------------------------|---------|
| Age (years)               | 67.6 (7.4)                  | 71.1 (8.2)             | 0.035*  |
| Height (cm)               | 152.2 (6.4)                 | 151.4 (5.7)            | 0.57    |
| Body weight (kg)          | 54.3 (10.8)                 | 52.3 (10.1)            | 0.32    |
| MI                        | 23.4 (4.4)                  | 22.8 (3.9)             | 0.73    |
| Disease Duration (years)  | 9.7 (5.1)                   | 11.3 (5.2)             | 0.12    |
| DMARDs use, n (%)         | 30 (60)                     | 25 (44.6)              | 0.12    |
| Tumorcept (50mg), n (%)   | 2 (4)                       | 3 (5.4)                | 0.74    |
| Olimumab (50mg), n (%)    | 4 (8)                       | 3 (5.4)                | 0.58    |
| Ocilizumab (162mg), n (%) | 8 (16)                      | 7 (12.5)               | 0.6     |
| Arilumab (200mg), n (%)   | 4 (8)                       | 4 (7.1)                | 0.86    |
| Batacept (125mg), n (%)   | 12 (24)                     | 8 (14.3)               | 0.2     |
| MTX use, n (%)            | 38 (76)                     | 26 (46.4)              | 0.02*   |
| MTX dose, mg/week         | 7.3 (1.8)                   | 6.5 (2.1)              | 0.11    |
| Rednisone use n (%)       | 22 (44)                     | 18 (32.1)              | 0.21    |
| Rednisone dose, mg/day    | 5.36 (1.4)                  | 5.4 (2.3)              | 0.72    |
| Modified Sharp Erosion Score | 36.1 (43.1)             | 29.6 (33.9)            | 0.63    |
| Modified Sharp JSN Score | 24.1 (36.5)                 | 23.1 (29.3)            | 0.21    |
| Modified Total Sharp Score| 60.1 (79.3)                 | 52.5 (62.5)            | 0.98    |
| AS28-CRP                  | 3.1 (1.1)                   | 2.83 (1.2)             | 0.28    |
| AS                        | 28.8 (17.7)                 | 29.2 (19.7)            | 0.82    |
| dHAQ                      | 0.52 (0.43)                 | 0.64 (0.77)            | 0.87    |
| CPA titer (U/ml)          | 109.7 (171.3)               | 141.1 (246.9)          | 0.56    |
| MMP3 (ng/ml)              | 94.3 (48.3)                 | 104.9 (69.9)           | 0.74    |
| MD                        |                            |                        |         |
| Lumbar spine (g/cm²)      | 0.89 (0.17)                 | 0.86 (0.16)            | 0.29    |
| Femoral neck (g/cm²)      | 0.58 (0.11)                 | 0.56 (0.11)            | 0.52    |
Results are expressed as the mean and standard deviation.

*p < 0.05 by Mann–Whitney U test

BMI, Body Mass Index; DMARDs, Disease-modifying antirheumatic drugs; MTX, methotrexate; DAS, Disease activity score; CRP, C-reactive protein; VAS, Visual analogue scale; HAQ, Health Assessment Questionnaire; ACPA, Anti-cyclic citrullinated peptide antibody; MMP3, Matrix metalloproteinase; BMD, Bone mineral density

Table 2 Comparison of the changes of ERO, JSN, mTSS scores and clinical scores at 12 months

| Variable                  | Bisphosphonate group (n=50) | Denosumab group (n=56) | p value |
|---------------------------|-----------------------------|------------------------|--------|
| Modified Sharp Erosion Score | 1.16 (1.47)                 | 0.72 (1.58)            | 0.015* |
| Modified Sharp JSN Score  | 0.24 (0.55)                 | 0.27 (0.84)            | 0.92   |
| Modified Total Sharp Score| 1.56 (2.15)                 | 1.12 (2.31)            | 0.01** |
| DAS28-CRP                 | 0.1 (0.74)                  | 0.04 (0.53)            | 0.9    |
| VAS                       | 0.96 (18.1)                 | 0.82 (15.7)            | 0.82   |
| mHAQ                      | 0.014 (0.23)                | 0.021 (0.31)           | 0.72   |

Results are expressed as the mean and standard deviation.

*p < 0.05; **p < 0.01 by Mann–Whitney U test

DAS, Disease activity score; CRP, C-reactive protein; VAS, Visual analogue scale; HAQ, Health Assessment Questionnaire

Table 3 Comparison of the changes of ERO, JSN, mTSS scores and clinical scores at 24 months

| Variable                  | Bisphosphonate group (n=50) | Denosumab group (n=56) | p value |
|---------------------------|-----------------------------|------------------------|--------|
| Modified Sharp Erosion Score | 1.56 (1.62)                 | 1.07 (2.38)            | 0.013* |
| Modified Sharp JSN Score  | 0.56 (1.1)                  | 0.61 (1.37)            | 0.67   |
| Modified Total Sharp Score| 2.52 (2.97)                 | 1.73 (4.36)            | 0.003**|
| DAS28-CRP                 | 0.18 (0.96)                 | 0.11 (0.72)            | 0.84   |
| VAS                       | 1.26 (20.5)                 | 0.98 (17.6)            | 0.87   |
| mHAQ                      | 0.019 (0.27)                | 0.026 (0.32)           | 0.78   |
Results are expressed as the mean and standard deviation.
*p < 0.05; **p < 0.01 by Mann–Whitney U test
DAS, Disease activity score; CRP, C-reactive protein; VAS, Visual analogue scale; HAQ, Health Assessment Questionnaire

Table 4 Comparison of the changes of bone mineral density and radiographic vertebral fractures at 12 months

| Variable                        | Bisphosphonate group (n=50) | Denosumab group (n=56) | p value |
|---------------------------------|-----------------------------|------------------------|---------|
| Lumbar spine (g/cm²)            | 0.034 (0.083)               | 0.033 (0.072)          | 0.32    |
| Femoral neck (g/cm²)            | 0.0045 (0.033)              | 0.021 (0.042)          | 0.011*  |
| Total hip (g/cm²)               | 0.0042 (0.056)              | 0.027 (0.062)          | 0.012*  |
| Vertebral fracture, n (%)       | 2 (4)                       | 1 (1.8)                | 0.49    |

Results are expressed as the mean and standard deviation.
*p < 0.05 by Mann–Whitney U test

Appendix Table 1

Appendix table 1 Comparison of the bisphosphonate and active vitamin D treatment

| Variable                        | Bisphosphonate group (n=50) | Denosumab group (n=56) | p value |
|---------------------------------|-----------------------------|------------------------|---------|
| Bisphosphonates                 |                             |                        |         |
| Alendronate (35mg), n (%)       | 16 (32)                     | 22 (39.3)              | 0.43    |
| Risedronate (17.5mg), n (%)     | 14 (28)                     | 13 (23.2)              | 0.57    |
| Minodronate (50mg), n (%)       | 20 (40)                     | 21 (37.5)              | 0.79    |
| Vitamin D                       |                             |                        |         |
| Eldecalcitol (0.75mg), n (%)    | 41 (82)                     | 51 (91.1)              | 0.17    |
| Alphacalcidol, (1mg), n (%)     | 9 (18)                      | 5 (8.9)                | 0.17    |